← Leaderboards
Michael R Grever
Ohio State University
$17,739,693
Attributed
$18,368,254
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–17$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$18,368,254 · 7
By mechanism
U01$9,256,988 · 2
UM1$3,815,981 · 1
P01$2,481,213 · 2
R01$1,495,978 · 1
P50$1,318,094 · 1
Top collaborators
- Robert S. Dipaola2 shared
Most similar at Ohio State University
Same institution · by research overlap
- Jennifer A. Woyach$6,733,332
- Steven M. Devine$8,239,113
- James Robert Fuchs$4,283,906
- William E. Carson$27,905,247
- William G Blum$1,308,600
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseClinical ResearchClinical TrialsPharmacodynamicsInvestigationApoptosisToxic EffectNovel TherapeuticsTherapeutic AgentsDrug KineticsPharmaceutical PreparationsOhioPre-ClinicalUniversitiesResponseNew AgentsDoseLaboratoriesChronic Lymphocytic LeukemiaAntineoplastic AgentsSafetyProgramsMalignant NeoplasmsPharmacogenomics
Grant awards (41)
Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis$300,000
UM1 · FY2017 · CA · contact PI
Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis$957,122
UM1 · FY2016 · CA · contact PI
UM1 Supplement for Early Therapeutic Trials with Phase 2 Intent$861,323
UM1 · FY2016 · CA · contact PI
Pharmacologic Inhibitors of Cellular Kinases and Signal Transduction$183,413
P01 · FY2016 · CA · contact PI
Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis$845,274
UM1 · FY2015 · CA · contact PI
Pharmacologic Inhibitors of Cellular Kinases and Signal Transduction$224,967
P01 · FY2015 · CA · contact PI
Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis$852,262
UM1 · FY2014 · CA · contact PI
Pharmacologic Inhibitors of Cellular Kinases and Signal Transduction$222,741
P01 · FY2014 · CA · contact PI
Phase I Trials of Anti-Cancer Agents$754,879
U01 · FY2013 · CA · contact PI
Pre-Clinical and Clinical Development of Silvestrol in Chronic Lymphocytic$251,385
P50 · FY2013 · CA · contact PI
Pharmacologic Inhibitors of Cellular Kinases and Signal Transduction$206,441
P01 · FY2013 · CA · contact PI
Phase I Trials of Anti-Cancer Agents$739,273
U01 · FY2012 · CA · contact PI
Pre-Clinical and Clinical Development of Silvestrol in Chronic Lymphocytic$270,040
P50 · FY2012 · CA · contact PI
Pharmacologic Inhibitors of Cellular Kinases and Signal Transduction$235,469
P01 · FY2012 · CA · contact PI
Phase I Trials of Anti-Cancer Agents$739,271
U01 · FY2011 · CA · contact PI
Pre-Clinical and Clinical Development of Silvestrol in Chronic Lymphocytic$256,794
P50 · FY2011 · CA · contact PI
Phase I Trials of Anti-Cancer Agents$762,134
U01 · FY2010 · CA · contact PI
Signal Transduction and Kinase Inhibition in CLL$313,273
P01 · FY2010 · CA · contact PI
Pre-Clinical and Clinical Development of Silvestrol in Chronic Lymphocytic$270,642
P50 · FY2010 · CA · contact PI
Phase I Trials of Anti-Cancer Agents$747,189
U01 · FY2009 · CA · contact PI
Phase I Trials of Anti-Cancer Agents$331,524
U01 · FY2009 · CA · contact PI
Signal Transduction and Kinase Inhibition in CLL$307,061
P01 · FY2009 · CA · contact PI
Pre-Clinical and Clinical Development of Silvestrol in Chronic Lymphocytic$269,233
P50 · FY2009 · CA · contact PI
Phase I Trials of Anti-Cancer Agents$725,427
U01 · FY2008 · CA · contact PI
Signal Transduction and Kinase Inhibition in CLL$289,786
P01 · FY2008 · CA · contact PI
Phase I Trials of Anti-Cancer Agents$701,378
U01 · FY2007 · CA · contact PI
Signal Transduction and Kinase Inhibition in CLL$286,908
P01 · FY2007 · CA · contact PI
Phase I Trials of Anti-Cancer Agents$602,401
U01 · FY2006 · CA · contact PI
Signal Transduction and Kinase Inhibition in CLL$211,154
P01 · FY2006 · CA · contact PI
Phase I Trials of Anti-Cancer Agents$604,449
U01 · FY2005 · CA
Phase I Trials of Anti-Cancer Agents$592,143
U01 · FY2004 · CA
Phase I Trials of Anti-Cancer Agents$574,899
U01 · FY2003 · CA
MOLECULAR STUDIES OF DRUG RESISTANCE IN CHRONIC LYMPHOCY$120,395
R01 · FY2003 · CA
MOLECULAR STUDIES OF DRUG RESISTANCE IN CHRONIC LYMPHOCY$474,393
R01 · FY2002 · CA
PHASE I TRIALS OF ANTICANCER AGENTS$384,566
U01 · FY2002 · CA
MOLECULAR STUDIES OF DRUG RESISTANCE IN CHRONIC LYMPHOCY$457,778
R01 · FY2001 · CA
PHASE I TRIALS OF ANTICANCER AGENTS$333,022
U01 · FY2001 · CA
MOLECULAR STUDIES OF DRUG RESISTANCE IN CHRONIC LYMPHOCY$443,412
R01 · FY2000 · CA
PHASE I TRIALS OF ANTICANCER AGENTS$362,455
U01 · FY2000 · CA
PHASE II CLINICAL TRIALS CONSORTIUM$158,395
U01 · FY2000 · CA
PHASE I TRIALS OF ANTICANCER AGENTS$143,583
U01 · FY2000 · CA